Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Buys $2,940,000.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMRGet Rating) Director Bvf Partners L. P/Il bought 150,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 5th. The shares were acquired at an average price of $19.60 per share, with a total value of $2,940,000.00. Following the completion of the transaction, the director now directly owns 1,975,767 shares of the company’s stock, valued at $38,725,033.20. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Kymera Therapeutics stock opened at $18.25 on Tuesday. The firm has a 50 day simple moving average of $36.70 and a 200-day simple moving average of $46.59. Kymera Therapeutics, Inc. has a 1-year low of $17.96 and a 1-year high of $69.12. The stock has a market cap of $943.96 million, a price-to-earnings ratio of -7.35 and a beta of 2.20.

Kymera Therapeutics (NASDAQ:KYMRGet Rating) last posted its quarterly earnings results on Tuesday, May 3rd. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.67) by ($0.04). Kymera Therapeutics had a negative net margin of 194.23% and a negative return on equity of 30.40%. The firm had revenue of $9.62 million during the quarter, compared to analysts’ expectations of $18.66 million. During the same period last year, the company earned ($0.29) EPS. The business’s quarterly revenue was down 48.6% on a year-over-year basis. On average, research analysts forecast that Kymera Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Several institutional investors have recently bought and sold shares of KYMR. Dark Forest Capital Management LP grew its stake in shares of Kymera Therapeutics by 3,292.0% in the 3rd quarter. Dark Forest Capital Management LP now owns 848 shares of the company’s stock valued at $50,000 after buying an additional 823 shares during the period. Nisa Investment Advisors LLC grew its stake in shares of Kymera Therapeutics by 57.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 1,227 shares of the company’s stock valued at $52,000 after buying an additional 447 shares during the period. O Shaughnessy Asset Management LLC acquired a new position in shares of Kymera Therapeutics in the 3rd quarter worth approximately $64,000. Wells Fargo & Company MN lifted its holdings in shares of Kymera Therapeutics by 60.9% in the 2nd quarter. Wells Fargo & Company MN now owns 1,430 shares of the company’s stock worth $69,000 after acquiring an additional 541 shares during the last quarter. Finally, Lazard Asset Management LLC acquired a new position in shares of Kymera Therapeutics in the 4th quarter worth approximately $78,000. 77.73% of the stock is owned by institutional investors and hedge funds.

A number of research analysts have weighed in on KYMR shares. Morgan Stanley decreased their price objective on shares of Kymera Therapeutics from $68.00 to $66.00 and set an “equal weight” rating for the company in a research report on Wednesday, March 2nd. Wells Fargo & Company started coverage on shares of Kymera Therapeutics in a research report on Thursday, February 10th. They issued an “overweight” rating and a $62.00 price objective for the company. B. Riley decreased their price objective on shares of Kymera Therapeutics from $67.00 to $50.00 in a research report on Wednesday, May 4th. Zacks Investment Research downgraded shares of Kymera Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 4th. Finally, Credit Suisse Group started coverage on shares of Kymera Therapeutics in a research report on Thursday, April 28th. They issued an “outperform” rating and a $63.00 price objective for the company. Five investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Kymera Therapeutics presently has an average rating of “Buy” and an average target price of $67.08.

About Kymera Therapeutics (Get Rating)

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

Read More

Insider Buying and Selling by Quarter for Kymera Therapeutics (NASDAQ:KYMR)

Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.